Overview

Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy

Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy
Phase:
Phase 2
Details
Lead Sponsor:
Acacia Pharma Ltd
Treatments:
Aprepitant
Dexamethasone
Fosaprepitant
Ondansetron